1507 / 1851
Take Home Message (DLBCL)
The development of tailored therapy according to the relapse risk
is warranted, rather than uniform treatment of all early-stage
DLCL (bulky disease, PET-oriented treatment)
Therapeutic burden: R-CHOP x 3 cycles followed by 30 Gy IF-RT
probably better than R-CHOP x 6 cycles (less toxic and probably
higher survival rates)
Consolidative RT is strongly recommended, even after 6 R-CHOP
and in advanced stage DLBCL, for patients with bulky lesions or
skeletal involvement